期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

格列奈类药物在肥胖2型糖尿病治疗中的系统评价 被引量：6

Systematic review on glinides in the treatment of obese type 2 diabetes
下载PDF
导出
摘要 早期相胰岛素分泌能力的损害是引起2型糖尿病及其并发症的重要因素之一。格列奈类药物是一种新型促胰岛素分泌剂,作用在胰岛β细胞膜上的ATP敏感的钾离子通道,起效快、作用时间短,较磺脲类药物能更好地控制餐后高血糖。其安全性良好,低血糖症发生率低,有着改善胰岛素抵抗,抗动脉粥样硬化等作用。可单独或与二甲双胍、基础胰岛素等联合使用。本文就格列奈类药物的作用机制及其在肥胖2型糖尿病患者中的应用作一概述。
作者 仉媛媛 丛丽
机构地区 哈尔滨医科大学附属第二医院内分泌科
出处 《药品评价》 CAS 2013年第9期33-35,40,共4页 Drug Evaluation
关键词 2型糖尿病 肥胖 格列奈列药物
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献16

  • 1Bickle JF. Meglitinide analogues: a review of clinical data focused on recent trials[J]. Diabetes Metab, 2006, 32(2): 113-120.
  • 2Sunaga Y, Gonni T, Shibasaki T, et al. The effect of mitiglinide KAD- 1229, a new anti-diabetic drug,on ATP-sensitive K+channels and insulin secretion:compa-rison with the sulfonylureas and nateglinide[J]. European Journal of Phar-macology, 2001, 314: 119-125.
  • 3冯玉欣,孙正凯,孙香.瑞格列奈治疗肥胖及非肥胖2型糖尿病疗效对比观察[J].山东医药,2011,51(13):60-61. 被引量：13
  • 4冯玉欣,逄力男,崔正放,孙丽萍,李培秀.瑞格列奈治疗肥胖及非肥胖2型糖尿病80例[J].中国新药杂志,2003,12(2):135-137. 被引量：2
  • 5李阳春,张华,花日葵,唐文辉.瑞格列奈对肥胖及非肥胖2型糖尿病的疗效对照[J].中国医学创新,2012,9(24):119-120. 被引量：4
  • 6Hollander PA, Schwarz SL, Gatlin MR, et al. Importance of early insulin secretion :comparison ofnateglinide and glyburide in previously diet-treated patients with type 2 diabetes[J]. Diabetes Care, 2001, 24(6): 983-988.
  • 7Kishikawa H, Okada Y, Kanda K, et al. Indication for type 2 diabetes mellitus [J]. JUOEG, 2005, 27(2): 179-188.
  • 8Taki H, Maki T, lso T, et al. Postmarketing study of nateglinide in Japan:treatment of medication-naive patients with type 2 diabetes[J]. Adv Ther, 2005, 22(6): 621-635.
  • 9Tentolouris N, Boutati E, Karambakalis N, et al. Acute nateglinide administration in subjects with type 2 diabetes:effects on postprandial metabolism, coagulation, and fibrinolysis[J]. Nutr Metab Cardivasc Dis, 2005, 15(1): 6-12.
  • 10Rizzo MR, Barbieri M, Grella R, et at. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal- test study[J]. Diabetes Metab, 2005, 31(3 Pt1): 255-260.

二级参考文献25

  • 1余绮玲,萧正华,陈定宇,王燕.瑞格列奈联合二甲双胍治疗2型糖尿病肥胖观察[J].实用糖尿病杂志,2007,3(1):27-28. 被引量：2
  • 2张维,毕娅欣.抵抗素基因多态性与2型糖尿病及肥胖相关性研究[J].实用全科医学,2007,5(6):478-479. 被引量：10
  • 3刘英敏.二甲双胍的临床合理应用与再评价[J].实用糖尿病杂志,1998,2:21-21.
  • 4王先令,陆菊明,潘长玉,翟淮伟.应用动态血糖监测系统评价瑞格列奈治疗新诊断2型糖尿病的疗效[J].中国糖尿病杂志,2007,15(7):426-428. 被引量：10
  • 5[1]Graul A, Castaner J. Repaglinide[J ]. Drugs Future, 1996, 21 (7):694 - 698.
  • 6[2]Fuhlendorff J. Molecular identification of a specific binding site(36Kda)for repaglinide[J]. Diabetes, 1998, 47:S416 - S502.
  • 7[3]Landgraf R, Bilo HJG. Repaglinide vs. glibendamide: a 14-week efficacy and safety comparison [ J ]. Diabetologia, 1997, 40 (Suppl,l): S321 - S326.
  • 8[4]Moses R. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes[J ]. Expert Opin Pharmacother, 2000, 1: 1455 - 1467.
  • 9[5]Marbury TC, Ruokle JL, Hatorp V, et al. Pharmacokinetics of repaglinide in subjects with renal impairment[J ]. Clin Pharmacol Ther, 2000, 67:7 - 15.
  • 10[6]Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glibenclamide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group[J]. Diabetes Care, 1999, 22:463 - 467.

共引文献30

同被引文献83

  • 1杨华章,陈亮,邝建,裴剑浩,李忠文,陈红梅,廖晓征,崔炎棠.餐时血糖调节剂瑞格列奈的临床应用[J].中国实用内科杂志,2001,21(4):248-250. 被引量：23
  • 2李娜,胡婕.瑞格列奈和格列吡嗪治疗肥胖及非肥胖2型糖尿病的临床比较[J].中国药物与临床,2006,6(1):71-71. 被引量：4
  • 3Chien HH, Chang CT, Chu NF, et al. Effect of Glybufide-Metformin Combination Tablet in Patients with Type 2 Diabetes [J]. J Chin Med Assoc, 2007,70( 11 ) : 473-480.
  • 4Michael N. Cook, PHD1, Cynthia J, etal. Comment on Hortg etal. Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease [J]. Diabetes Care, 2005,28 (5) :995-1000.
  • 5FDA. Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone- containing diabetes medicines (http:// www.fda.gov/drugs/drugsafety/ ucm376389.htm).
  • 6Fonseca V, Rosenstock J, Patwardhan R,et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial [J]. JAMA. 2000,283 ( 13 ) : 1695-1702.
  • 7Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study [J]. Diabetes Metab Res Rev, 2005,21(2) : 167-174.
  • 8Raskin P, Lewin A, Reinhardt R, et al. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glyeaemic control [J]. Diabetes Obes Metab, 2009,11 (10) : 947-952.
  • 9John W Richard, Philip Raskin. improved glycemic control with repaglinide- metformin in fixed combination for patients with type 2 diabetes [J]. Clin Med Insights Endocrinol Diabetes, 2011,4 : 29-37.
  • 10Bo Ahr~n. Novel combination treatment of type 2 diabetes DPP-4 inhibition + mefformin [J]. Vascular Health and Risk Management, 2008,4(2) :383-394.

引证文献6

二级引证文献23

药品评价
2013年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部